Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856320 | 0.89 | PIK3CA (0.49) | PIK3CAPRKDCNR1H2MTORCREBBP | |
| SCHEMBL3752728 | 0.85 | PIK3CA (0.62) | PIK3CAPRKDCNR1H2MTORCREBBP | |
| SCHEMBL30405764 | 0.85 | PIK3CA (0.62) | PIK3CAPRKDCNR1H2MTORCREBBP | |
| SCHEMBL856311 | 0.85 | PIK3CA (0.48) | PIK3CAPRKDCNR1H2MTORCREBBP | |
| SCHEMBL3749745 | 0.81 | PIK3CA (0.49) | PIK3CAPRKDCMTORRIPK1 | |
| SCHEMBL856145 | 0.81 | NR1H2 (0.48) | PIK3CAPRKDCNR1H2GPR119CREBBP | |
| SCHEMBL3756231 | 0.80 | PIK3CA (0.70) | PIK3CAMTORCREBBP | |
| SCHEMBL2724334 | 0.80 | PIK3CA (0.47) | PIK3CAPRKDCMTORCREBBPRIPK1 | |
| SCHEMBL3765369 | 0.80 | PIK3CA (0.45) | PIK3CAPRKDCNR1H2GPR119CREBBP | |
| SCHEMBL15399388 | 0.79 | PIK3CA (0.46) | PIK3CAPRKDCMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005172-A1 | Benzoxazepines as Inhibitors of PI3K/M TOR and Methods of Their Use and Manufacture | ELELIXIS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2643319-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012074869-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005172-A1 | Benzoxazepines as Inhibitors of PI3K/M TOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3R2 | PIK3CA 4/4885PRKDC 2472/4885NR1H2 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.